Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic by McGregor, CG, Adams, A, Sadler, R, Arancibia-Cárcamo, CV, Palmer, R, Ambrose, T, Brain, O, Walsh, A, Klenerman, P, Travis, SP, Croft, NM, Lindsay, JO, Satsangi, J

Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response by Adams, A, Gupta, V, Mohsen, W, Chapman, TP, Subhaharan, D, Kakkadasam Ramaswamy, P, Kumar, S, Kedia, S, McGregor, CG, Ambrose, T, George, BD, Palmer, R, Brain, O, Walsh, A, Ahuja, V, Travis, S, Satsangi, J